Single-nucleotide variants in microRNAs associated with breast cancer in women from western Mexico

Table 3 Association between rs11614913 with histological and immunohistochemical subtypes of breast cancer, n (%)

rs11614913 C>T		Cases	Control	Model comparison		OR (95%CI)	P value
Breast cancer ductal
Genotype	-	n = 37	n = 215	-	C/C vs C/T	0.7296 (0.3932-1.3439)	0.3091
	C/C	15 (40)	77 (36)	MC	C/C vs T/T	1.4259 (0.6970-2.9171)	0.3312
	C/T	11 (30)	102 (47)	-	C vs T	1.1402 (0.7770-1.6732)	0.5024
	T/T	11 (30)	36 (17)	Do	C/C vs C/T + T/T	0.8184 (0.4011-1.6696)	0.5816
Allele	-			Re	C/C + C/T vs T/T	2.1036 (0.9541-4.6383)	0.0653
	C	41 (55)	256 (60)	OD	C/C + T/T vs C/T	0.4687 (0.2205-0.9963)	0.0489a
	T	33 (45)	174 (40)	L-ad		0.85 (0.53-1.38)	0.5200
Breast cancer lobular
Genotype	-	n = 13	n = 215	MC	C/C vs C/T	-	-
	C/C	6 (36)	77 (36)	MC	C/C vs T/T	-	-
	C/T	5 (47)	102 (47)	-	C vs T	-	-
	T/T	2 (15)	36 (17)	Do	C/C vs C/T + T/T	-	-
Allele	-			Re	C/C + C/T vs T/T	-	-
	C	17 (65)	256 (60)	OD	C/C + T/T vs C/T	0.6924 (0.2195-2.1845)	0.5306
	T	9 (35)	174 (40)	L-ad		1.28 (0.56-2.91)	0.5600
Breast cancer mixed
Genotype	-	n = 5	n = 215	-	C/C vs C/T	-	-
	C/C	1 (20)	77 (36)	MC	C/C vs T/T	-	-
	C/T	4 (80)	102 (47)	-	C vs T	-	-
	T/T	0 (0)	36 (17)	Do	C/C vs C/T + T/T	-	-
Allele	-			Re	C/C + C/T vs T/T	-	-
	C	6 (60)	256 (60)	OD	C/C + T/T vs C/T	-	-
	T	4 (40)	174 (40)	L-ad		-	-
Breast cancer HR+/LA
Genotype	-	n = 36	n = 215	-	C/C vs C/T	1.5139 (0.6968-3.2891)	0.2948
	C/C	16 (44)	77 (36)	MC	C/C vs T/T	0.8021 (0.2897-2.2206)	0.6712
	C/T	14 (39)	102 (47)		C vs T	0.8316 (0.4954-1.3960)	0.4853
	T/T	6 (17)	36 (17)	Do	C/C vs C/T + T/T	0.6975 (0.3415-1.4244)	0.3227
Allele	-			Re	C/C + C/T vs T/T	0.9944 (0.3858-2.5632)	0.9908
	C	46 (64)	256 (60)	OD	C/C + T/T vs C/T	0.7050 (0.3426-1.4506)	0.3424
	T	26 (36)	174 (40)	L-ad		1.20 (0.72-1.99)	0.4900
Breast cancer TP/LB
Genotype	-	n = 13	n = 215	-	C/C vs C/T	-	-
	C/C	4 (31)	77 (36)	MC	C/C vs T/T	-	-
	C/T	3 (23)	102 (47)	-	C vs T	2.0063 (0.9001-4.4718)	0.0886
	T/T	6 (46)	36 (17)	Do	C/C vs C/T + T/T	-	-
Allele	-			Re	C/C + C/T vs T/T	-	-
	C	11 (42)	256 (60)	OD	C/C + T/T vs C/T	0.33 (0.089-1.241)	0.1013
	T	15 (58)	174 (40)	L-ad		0.51 (0.230-1.130)	0.0940
Breast cancer HER2+
Genotype	-	n = 9	n = 215	-	C/C vs C/T	-	-
	C/C	8 (89)	77 (36)	MC	C/C vs T/T	-	-
	C/T	1 (11)	102 (47)	-	C vs T	1.4713 (0.5725-3.7808)	0.4226
	T/T	0 (0)	36 (17)	Do	C/C vs C/T + T/T	-	-
Allele	-			Re	C/C + C/T vs T/T	-	-
	C	17 (94)	256 (60)	OD	C/C + T/T vs C/T	-	-
	T	1 (6)	174 (40)	L-ad		0.69 (0.27-1.74)	0.4300
Breast cancer TN
Genotype	-	n = 5	n = 215	-	C/C vs C/T	-	-
	C/C	5 (100)	77 (36)	MC	C/C vs T/T	-	-
	C/T	0 (0)	102 (47)	-	C vs T	-	-
	T/T	0 (0)	36 (17)	Do	C/C vs C/T + T/T	-	-
Allele	-			Re	C/C + C/T vs T/T	-	-
	C	10 (100)	256 (60)	OD	C/C + T/T vs C/T	-	-
	T	0 (0)	174 (40)	L-ad		0.69 (0.20-2.37)	0.5500

^aP < 0.05.

OR: Odds ratio; CI: Confidence interval; MC: Multiple comparison; Do: Dominant model; Re: Recessive model; OD: Over-dominant model; L-ad: Log-additive model; HR+: Hormone receptor positive; LA: Luminal A; TP: Triple positive; LB: Luminal B; HER2+: Human epidermal growth factor 2 positive.